Question · asked by 1 review
Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy: Quality of life ‐ not measured
- Population
- treatment‐resistant depression in adults
- Intervention
- Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d)
- Comparison
- augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy
- Outcome
- Quality of life ‐ not measured
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy Quality of life ‐ not measured · treatment‐resistant depression in adults The review found no eligible studies for this question. Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.